Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Passage BIO, Inc.

PASG · Nasdaq · CIK 0001787297 · Healthcare · Biotechnology

INSIDER SIGNAL

42.9 / 100

1 buyers · 1 purchase transaction lines · $206.2K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+10.4 / 25
Role+14.0 / 20
Recency+1.5 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Lynx1 Capital Management LP; Nichols WestonTenPercentOwner
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Lynx1 Capital Management LP; Nichols Weston · $206.2K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-06-25–2026-06-25

Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

42.9 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 43.2
  2. 43.1
  3. 43.0
  4. 43.0
  5. 42.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
2Sales
2Other Form 4 lines
3SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-26.0%
3M
-17.3%
6M
-62.7%
12M
-55.4%

Volatility & liquidity

Volatility
126.7%
Beta
—
Avg daily value
USD 90,698

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-242.7%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
90,840
Previous report
97,008
Avg daily volume
24,739
Days to cover
3.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-25Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")50,055USD 4.12USD 206,227SEC filing ↗
2025-09-15Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock11,900USD 6.99USD 83,181SEC filing ↗
2025-09-12Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock19,783USD 6.99USD 138,283SEC filing ↗
2025-09-11Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share (Common Stock)325USD 6.96USD 2,262SEC filing ↗
2025-07-24Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock66,423USD 5.71USD 379,275SEC filing ↗
2025-07-23Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock49,302USD 5.74USD 282,993SEC filing ↗
2025-07-22Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")13,123USD 5.44USD 71,389SEC filing ↗
2024-12-27Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share373,645USD 0.65USD 242,869SEC filing ↗
2024-11-27Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock29,300USD 0.67USD 19,631SEC filing ↗
2024-11-26Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common Stock167,055USD 0.71USD 118,609SEC filing ↗
2024-11-25Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")259,998USD 0.56USD 145,599SEC filing ↗
2023-06-28ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock575,195USD 0.84USD 483,164SEC filing ↗
2023-06-27ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock617,382USD 0.84USD 518,601SEC filing ↗
2022-05-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock303,500USD 1.94USD 588,790SEC filing ↗
2022-05-03ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock221,500USD 1.93USD 427,495SEC filing ↗

Form 4 evidence

5 transaction lines in the latest 365-day window; 119 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-25Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")50,055USD 4.12USD 206,227SEC filing ↗
2026-01-08Chou WilliamSale (S)Common Stock4,076USD 18.44USD 75,161SEC filing ↗
2026-01-08Chou WilliamOption exercise / conversion (M)Common Stock10,000USD —USD —SEC filing ↗
Show recent Form 4 evidence (5 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-25Lynx1 Capital Management LP; Nichols WestonPurchase (P)Common stock, $0.0001 par value per share ("Common Stock")50,055USD 4.12USD 206,227SEC filing ↗
2026-01-08Chou WilliamSale (S)Common Stock4,076USD 18.44USD 75,161SEC filing ↗
2026-01-08Chou WilliamOption exercise / conversion (M)Common Stock10,000USD —USD —SEC filing ↗
2026-01-08Borthwick KathleenSale (S)Common Stock2,062USD 18.44USD 38,023SEC filing ↗
2026-01-08Borthwick KathleenOption exercise / conversion (M)Common Stock5,000USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPASG
CIK0001787297
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history119 transaction lines from 2020-02-28 to 2026-06-25
45 P purchase lines · 43 S sale lines · 31 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.